Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
|Articles|September 3, 2014
Erectile dysfunction: Multiple treatment options
This video presents a thorough description of all the treatment options available for erectile dysfunction, including their administration, benefits, and limitations.
Advertisement
In this video, I present a thorough description of all the treatment options available for erectile dysfunction, including their administration, benefits, and limitations.
James M. Hotaling, MD, MS, Section Editor
Dr. Hotaling is assistant professor of surgery (urology) at the
More 'Y'tube videos
Advertisement
Related to this article
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC
2
Urocross Expander System enters US commercial use for symptomatic BPH
3
Study assesses real-world outcomes with intranasal vardenafil for ED
4
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
5